title: Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002614:Chelating Agents / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D058990:Molecular Targeted Therapy; D011929:Razoxane / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013318:Stroke Volume / Q000187:drug effects; D000068878:Trastuzumab
chemical_list: D018943:Anthracyclines; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D002316:Cardiotonic Agents; D002614:Chelating Agents; D011929:Razoxane; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human